Biohaven Pharma (BHVN) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $63 at Jefferies
March 5, 2025 5:21 AM ESTJefferies analyst Amy Li lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $63.00 (from $64.00) while maintaining a Buy rating.
The analyst comments "BHVN provided program updates during Q4 earnings. Our thoughts - BHV-1300: While we see +'ves in data (~80% median... More
